Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years

25 Jan 2025

Abstract excerpt

BACKGROUND: Lenacapavir is a highly potent first-in-class inhibitor of HIV-1 capsid that was approved for the treatment of heavily treatment-experienced people with HIV-1 harboring multidrug-resistant virus, and it is used in combination with an optimized background regimen (OBR). Resistance analyses conducted after 2 years of lenacapavir treatment in the phase 2/3 CAPELLA study are described. METHODS: CAPELLA...

Topics

Join the communities discussing this publication.

Biological Research and Disease Studies
HIV/AIDS drug development and treatment
HIV Research and Treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39873394
DOI: 10.1093/infdis/jiaf050

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 YearsPMID 39873394Read ↗

Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLASemantic proximity Read ↗

Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.Semantic proximity Read ↗

Baseline and week 48 resistance analysis in participants receiving bictegravir + lenacapavir in the phase 2 ARTISTRY-1 study.Semantic proximity Read ↗

Lenacapavir treatment-emergent HIV-1 capsid resistance mutations are frequently associated with replication defects.Semantic proximity Read ↗

Week 96 resistance analysis in participants receiving bictegravir/lenacapavir in the phase 2 ARTISTRY-1 study.Semantic proximity Read ↗

Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.Semantic proximity Read ↗

Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxisSemantic proximity Read ↗

Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy With Lenacapavir-containing RegimenSemantic proximity Read ↗

Design and Evaluation of Next-Generation HIV Genotyping for Detection of Resistance Mutations to 28 Antiretroviral Drugs Across 5 Major Classes Including Lenacapavir.Semantic proximity Read ↗

Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavirSemantic proximity Read ↗

Recurrent and novel evolutionary pathways drive in vitro HIV-1 lenacapavir resistance with diverse phenotypic consequences.Semantic proximity Read ↗

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.